

## Correction



# Correction: Building in vitro models of the brain to understand the role of *APOE* in Alzheimer's disease

Rebecca L Pinals<sup>1,2</sup> , Li-Huei Tsai<sup>1,2,3</sup> 

<sup>1</sup>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA <sup>2</sup>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA <sup>3</sup>Broad Institute of Harvard and MIT, Cambridge, MA, USA

Correspondence: [lhtsai@mit.edu](mailto:lhtsai@mit.edu)

DOI <https://doi.org/10.26508/lisa.202201845> | Received 22 November 2022 | Accepted 23 November 2022 | Published online 1 December 2022

Article: Pinals RL, Tsai L-H (2022 Sep 27) Building in vitro models of the brain to understand the role of *APOE* in Alzheimer's disease. Life Sci Alliance 5(11): e202201542. doi: [10.26508/lisa.202201542](https://doi.org/10.26508/lisa.202201542). PMID: 36167428.

In the initially published version of this article, a section in the Introduction reads:

In the amyloidogenic pathway,  $\beta$ -secretase first cleaves APP at the ectodomain, followed by  $\gamma$ -secretase at the intramembrane site, liberating the longer A $\beta$ -42 species. This contrasts with the physiologically normal pathway in which  $\alpha$ - then  $\gamma$ -secretases consecutively cleave APP, shedding the shorter A $\beta$ -40 species.

This section should instead read:

In the amyloidogenic pathway,  $\beta$ -secretase first cleaves APP at the ectodomain, followed by  $\gamma$ -secretase at the intramembrane site, liberating A $\beta$  peptides including A $\beta$ -40 and A $\beta$ -42 (among other peptide lengths).



**License:** This article is available under a Creative Commons License (Attribution 4.0 International, as described at <https://creativecommons.org/licenses/by/4.0/>).